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Potassium permeabilityAromatic aldehydes like o-vanillin were designed to reduce the complications of sickle cell disease (SCD) by in-
teraction with HbS, to reduce polymerisation and RBC sickling. Present results show that o-vanillin also directly
affects RBC membrane permeability. Both the K+–Cl− cotransporter (KCC) and the Ca2+-activated K+ channel
(or Gardos channel) were inhibited with IC50 of about 0.3 and 1 mM, respectively, with activities almost
completely abolished by 5 mM. Similar effects were observed in RBCs treated with the thiol reacting reagent
N-ethylmaleimide or with the Ca2+ ionophore A23187, to circumvent any action via HbS polymerisation. The
deoxygenation-induced cation conductance (sometimes termed Psickle) was partially inhibited, whilst
deoxygenation-induced exposure of phosphatidylserine was completely abrogated. Na+/K+ pump activity was
also reduced. Notwithstanding, o-vanillin stimulated K+ efﬂux through an unidentiﬁed pathway and resulted
in reduction in cell volume (asmeasured bywetweight− dryweight). These actions are relevant to understand-
ing how aromatic aldehydes may affect RBC membrane permeability per se as well as HbS polymerisation and
thereby inform design of compounds most efﬁcacious in ameliorating the complications of SCD.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
The complications of sickle cell disease (SCD) are two-fold: a chronic
anaemia subsequent to increased red blood cell (RBC) destruction and
acute ischaemic signs following blockage of the microvasculature
[1–3]. Signs depend on the organ involved and can be numerous. Sever-
ity, however, varies considerably between individuals. Notwithstanding
this variability, all complications result from polymerisation of the ab-
normal form of haemoglobin, HbS, present in patients' RBCs. HbS has a
single amino acid substitution at a critical site on the haemoglobin mol-
ecule [4,5]. At the β6 position, glutamic acid is replaced by valine and
the loss of negative charge enables neighbouring HbS molecules to ag-
gregate on deoxygenation, forming long rigid polymers which distort
RBC shape and cause other deleterious abnormalities, including altered
rheology, elevated membrane permeability and increased fragility [5].
At present, no speciﬁc treatment is available and management is
usually supportive depending on whatever complication is most pro-
nounced [1,3]. Recently, hydroxyurea has received attention as a drug
of choice for ameliorating SCD complications [6–8]. Hydroxyurea's efﬁ-
cacy appears to depend on its ability to increase expression of fetal Hb,
HbF—although other mechanisms may also be involved. HbF is not in-
corporated into HbS polymers and also serves to dilute the intracellular. This is an open access article underconcentration of HbS, thereby reducing the tendency to polymerisation
and sickling. Hydroxyurea is not without risks, however, being poten-
tially teratogenic, with variable response, and also having issues of
non-compliance [8]—factors which restrict its use to more severely af-
fected individuals.
As a result, there is a continued search for other effective therapies.
An alternative approach has been to reduce directly the tendency for
HbS to polymerise on deoxygenation. In this context, a variety of aro-
matic aldehydes (and related compounds) have been tested, of which
o-vanillin is a well known member [9–11]. These reagents form Schiff
bases with HbS, increasing its oxygen afﬁnity, and thereby reducing po-
lymerisation and RBC sickling. Some have also been reported to inter-
fere with RBC permeability [12], but although of potential importance,
this aspect has not been widely investigated.
Several abnormal, or abnormally regulated, cation transporters par-
ticipate in the pathogenesis of SCD [13–15]. These include the K+–Cl−
cotransporter (or KCC) and the Ca2+-activated K+ channel (or Gardos
channel), transport systemswhosemolecular identities are established.
A third pathway, sometimes termed Psickle, is activated byHbS polymer-
isation and RBC shape change [13,16]. Psickle is thought to function pre-
dominantly as a deoxygenation-induced cation pathway. Although it
remains enigmatic at a molecular level, Psickle will allow entry of Ca2+
[17,18], and loss of Mg2+ [19,20], with subsequent activation of the
Gardos channel and perhaps KCC. The three pathways interact tothe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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reduces the lag time for polymerisation upon deoxygenation—
hence increasing the likelihood of sickling and ischaemia in the
microvasculature.
In this report, radioactive tracer methodologies have been used to
investigate the effects of ortho (o)-vanillin on K+ permeability, KCC,
the Gardos channel and Psickle in RBCs from SCD patients. Results show
that this aromatic aldehyde markedly inhibits all three, as well as also
affects HbS polymerisation and sickling, but also stimulates an uniden-
tiﬁed K+ efﬂux pathway. These additional actions of o-vanillin may be
of signiﬁcant considerationwhen designing similar compounds to ame-
liorate the complications of SCD.
Materials and methods
Chemicals
Bumetanide, 3-[N-morpholino] propane sulfonic acid (MOPS), N-
ethylmaleimide, ouabain, ortho (o)-vanillin, and salts were purchased
from Sigma Chemical Co. (Poole, Dorset, UK). Clotrimazole and
A23187 were purchased from Calbiochem (Nottingham, UK). 86Rb+
was supplied by Perkin Elmer (Beaconsﬁeld, UK).
Sample collection and handling
Blood sampleswere obtained by venepuncture of patients with sick-
le cell disease (SCD), both homozygous HbSS and heterozygous HbSC,
with permission under ethical consent, using the anticoagulant EDTA.
Samples were kept at 4 °C until use within 48 h.
Solutions and tonometry
The standard saline (MBS) comprised (in mM): 145 NaCl, 1.1 CaCl2,
5 glucose and 10 MOPS, (pH 7.4 at 37 °C; 290± 5 mOsmol kg−1 H2O).
For experiments in which Cl− dependence of K+ inﬂux was examined,
NO3−-containing salts replaced those containing Cl−. To prevent the
rapid RBC shrinkage which would otherwise occur following maximal
stimulation of the Gardos channel in experiments inwhich intracellular
Ca2+ was directly raised by incubation with the Ca2+ ionophore
A23187, a high-K+- and low-Ca2+-containing salinewas used, compris-
ing (in mM): 80 KCl, 70 NaCl, 0.01 CaCl2, 0.15 MgCl2, 5 glucose and 10
MOPS. The wash solution to remove unincorporated 86Rb+ comprised
isotonic MgCl2 (107 mM), buffered with MOPS (10 mM), pH 7.4 at
4 °C. Stock solutions of bumetanide (10 mM) were prepared in
100 mM Tris base and used at a ﬁnal concentration of 10 μM. Stock
solutions of ouabain (10 mM) were prepared in distilled water and
used at a ﬁnal concentration of 100 μM. Stocks of clotrimazole (CLT;
5 mM) were prepared in DMSO and used at ﬁnal concentrations of
5 μM. After washing whole blood and removal of plasma and buffy
coat, in most experiments RBC suspensions were placed in tonometers
(Eschweiler, Kiel, Germany) at 20% haematocrit (Hct), to equilibrate
at the requisite O2 tension. Tonometers were ﬂushed with warm, hu-
midiﬁed gas mixtures, supplied at the appropriate O2 tension using a
Wösthoff gas mixing pump [21]. For CLT, dissolved in DMSO, appropri-
ate controls were all treated with the same concentration of solvent
(b0.1% ﬁnal).
K+ ﬂux measurements
To determine the activity of the K+ transport pathways, K+ inﬂuxwas
usually measured at 37 °C using 86Rb+ as a congener for K+ [22,23]. Cells
were taken from the tonometers and diluted 10-fold into saline, pre-
equilibrated at the appropriate O2 tension, at 260 mOsm kg−1 and
pH 7, conditions chosen in order to stimulate the K+–Cl− cotransporter
(KCC). 86Rb+ was added in 150 mM KNO3 to give a ﬁnal [K+] of
7.5 mM in all experiments except those with HK saline and A23187-treated RBCs. After incubation with radioisotope for 10 min, RBCs were
washed to remove extracellular 86Rb+, ﬁve-times in an ice-cold MgCl2
wash solution. For K+ efﬂux experiments, RBCs were loaded overnight
at 4 °C by addition of 86Rb+ after which cells were washed ﬁve times in
an ice-cold wash solution. RBCs were then suspended at 2% haematocrit
(Hct) in standard saline at 37 °C. Aliquots were taken at 5 min intervals
for 30–60 min and spun through phthalate oil. The cell pellet was lysed
with detergent, deproteinised with TCA, and counted by liquid scintilla-
tion (cpm). A semilog plot (of cpm at time = t/cpm at time = 0) was
used to determine the rate constant for K+ efﬂux. Except for experiments
to measure Na+/K+ pump activity, ouabain (100 μM) and bumetanide
(10 μM) were present in all experiments to obviate any K+ transport
through the Na+/K+ pump and the Na+–K+–2Cl− cotransporter, respec-
tively. Either microhaematocrit determination or the cyanohaemoglobin
method was used to measure the ﬁnal Hct. KCC activity was assayed as
Cl−-dependent K+ inﬂux; Gardos channel activity as the CLT-sensitive
(5 μM) K+ inﬂux; Na+/K+ pump activity as the ouabain-sensitive
(100 μM) K+ inﬂux and Psickle as the deoxygenation-induced K+ inﬂux
measured in the absence of Cl−.
Labelling of phosphatidylserine exposure
For phosphatidylserine (PS) labelling, 5 μl aliquots (105 RBCs) of
each sample were placed in 250 μl of LA-FITC binding buffer and incu-
bated in the dark at room temperature for 10 min. RBCs were then
pelleted by centrifugation for 10 s at 16,100 g, washed once in LK or
HK HBS to remove unbound LA-FITC and kept on ice until ﬂow cytome-
try analysis. Unlike annexin-V, LA-FITC binds to PS in a Ca2+-indepen-
dent manner and control experiments showed that binding was
irreversible. Inhibitors were tested for self-ﬂuorescence at their highest
concentration with unlabelled RBCs.
FACS acquisition and analysis
Externalised PS was measured with FITC using an excitation wave-
length of 488 nm in the FL1 channel with an emission wavelength of
519 nm on a ﬂuorescence-activated ﬂow cytometer (FACSCalibur,
Becton Dickinson, BD) and analysed with the BD CellQuest Pro software
using a protocol published previously [24]. Measurements were taken
using a logarithmic gain. Forward scatter (FSC, size) and side scatter
(SSC, granularity) gates for RBCs were identiﬁed in control experiments
using anti-glycophorin A-PE labelled RBCs. The positive ﬂuorescent gate
was set using RBCs unlabelled with FITC-LA. For each measurement,
10,000 events were gated. PS positive cells were deﬁned as all events
falling within the preset FSC, SSC and positive ﬂuorescent gates.
Measurements of RBC sickling
RBCs were incubated in tonometers at 2% Hct for up to 60 min after
which sampleswere ﬁxed in the same solution as that used during incu-
bation but with the addition of 0.3% glutaraldehyde. Control experi-
ments showed that this protocol was sufﬁcient to maintain the RBC
shape for several weeks. Sicklingwas assessed by lightmicroscopy. Sev-
eral hundred RBCs (typically 300–400) were counted using an Im-
proved Neubauer haemocytometer (in ﬁve 1 mm × 1 mm squares, the
central one and the four corners).
Measurement of cell water content
Cell water content was measured by the wet weight− dry weight
method [25]. In brief, RBCs were pelletted by centrifugation at 12,000
g for 10 min at 4 °C. The extruded pellet was weighed immediately
(to 0.01 mg) and again after drying for 18 h at 95 °C. Water content
was expressed as ml water per g dry cell solids (ml/g dcs).
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Fig. 2. Effect of o-vanillin on the potassium permeability of RBCs from patients with SCD.
Activity of the K+–Cl− cotransport (KCC)was determined as the Cl−-dependent K+ inﬂux
in fully oxygenated RBCs from homozygous HbSS individuals. Activity of Psickle was deter-
mined as the deoxygenation-induced Cl−-independent K+ inﬂux in N2; that of the Gardos
channelwas determined as the clotrimazole (CLT; 5 μM)-sensitive K+ inﬂux—both in fully
deoxygenated RBCs. o-Vanillin (5 mM) was present either during the period of measure-
ment of transporter activity only, or, in addition, during 30 min pre-incubation as well.
Flux measurements are normalised to those measured in control RBCs in the absence of
o-vanillin and presented as a percentage of their maximal value, which, for HbSS were
2.35 ± 0.45 mmol (l cells h)−1 for KCC in air, 1.02 ± 0.22 for Psickle and 5.80 ± 1.16 for
the Gardos channel. Data represent means ± S.E.M. for 4–7 determinations.
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Results are presented as single observations representative of at
least 3 others, or as means ± S.E.M. of n observations. Where appropri-
ate, comparisonsweremade using paired Student's t tests, with p b 0.05
being considered signiﬁcant.
Results
The effect of o-vanillin on sickling
In the ﬁrst series of experiments, the effect of o-vanillin (5mM)was
tested on sickling of RBCs fromHbSS patients (Fig. 1). In fully deoxygen-
ated RBCs, therewas only a small reduction in percentage sickling (N.S.)
in the presence of o-vanillin. At higher O2 tensions, nearer the P50 for O2
saturation of Hb, greater effects were observed, however, so that at an
O2 tension of 15 mm Hg, sickling was inhibited by about 75% in the
presence of o-vanillin (Fig. 1).
The effect of o-vanillin on K+ transport in RBCs from SCD patients
The effects of o-vanillin (5 mM) were then tested on the main cation
pathways which mediate solute loss and dehydration of RBCs from SCD
patients, under fully oxygenated and fully deoxygenated conditions. Re-
sults are shown in Fig. 2 for RBCs from homozygous (HbSS) patients. In
the presence of o-vanillin, KCC in oxygenated RBCs was substantially
inhibited (by about 75%). Pre-treatment with o-vanillin for 30 min prior
to ﬂux measurement produced a slight increase in inhibition. In these
RBCs, KCC activity was reduced by about half by deoxygenation and this
residual oxygen-insensitive component of KCC was also sensitive to o-
vanillin (inhibition of this component of KCC activitywas 73±13%with-
out pre-treatment,means± S.E.M.,n=5). For Psickle activity, the effect of
o-vanillin in the absence of pre-treatment was insigniﬁcant. Following
pre-incubation with o-vanillin, however, Psickle activity was inhibited by
about 50% (Fig. 2). Consistent with an inhibitory effect on Psickle,
deoxygenation-induced phosphatidylserine exposure was completely
inhibited by incubation in the presence of o-vanillin (Fig. 3). Effects on
deoxygenation-activated Gardos channel activity were also determined.
As for KCC, substantial inhibition (about 80%) was observed without
pre-treatment (Fig. 2). In these experiments and similar to ﬁndings
shown in Fig. 1, following complete deoxygenation sicklingwas unaffect-
ed by the presence of o-vanillin (being 98±4%,mean± S.E.M., n=5, of
control values in the absence of o-vanillin). Itwould therefore appear that100 15 10 0
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Fig. 1. Sickling of red blood cells (RBCs) from homozygous (HbSS) patients with sickle cell
disease (SCD). RBCswere incubated for 20min in tonometers at 2% haematocrit at the ox-
ygen tension indicated. Aliquotswere then ﬁxed in saline pre-equilibrated at the same ox-
ygen tension with the addition of glutaraldehyde (0.3%). Morphological sickling was
determined by light microscopy. Histograms represent means ± S.E.M., n= 3.o-vanillin can substantially inhibit both KCC and the Gardos channel
without any inhibition of HbS polymerisation and sickling. Similar ﬁnd-
ingswere obtainedusing RBCs from the secondmain genotypeof SCDpa-
tients, heterozygous HbSC individuals, with KCC and Gardos channel
activities reduced to b20% their magnitude in the absence of o-vanillin
(5 mM).The effect of o-vanillin on N-ethylmaleimide-treated RBCs from
SCD patients
KCC activity is controlled by protein phosphorylation, involving
cascades of regulatory protein kinases (PK) and phosphatases (PP), on
both serine–threonine and tyrosine residues [26,27]. The inhibitory ac-
tion of o-vanillin could therefore be mediated via this cascade. To-20 0 20 40 60 80
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Fig. 3. The effect of o-vanillin on deoxygenation-induced phosphatidylserine (PS) expo-
sure in RBCs from patients with SCD. Suspensions of RBCs (0.5% Hct) were deoxygenated
in the standard saline (1.1 mM [Ca2+]o) in Eschweiler tonometers. Control RBCs (black
circles) or in the presence of 1.25 mM o-vanillin (grey squares) were incubated in air
for 20 min prior to the beginning of deoxygenation. Symbols represent mean ± S.E.M.
for n= 6. * p b 0.02, ** p b 0.005 (Student's t test).
24 A. Hannemann et al. / Blood Cells, Molecules and Diseases 53 (2014) 21–26investigate this possibility, RBCswere pre-treatedwithN-ethylmaleimide
(NEM; 1 mM), a thiol-reacting reagent which activates KCC activity and
abolishes its sensitivity to (de)phosphorylation [26]. Under these condi-
tions, substantial inhibition of KCC activity by o-vanillin (5 mM) was
still observed in RBCs from both HbSS and HbSC individuals (Figs. 4a &
b). The IC50 for o-vanillin on KCC activity in NEM-treated RBCs from
HbSS patients was about 0.3 mM (Fig. 4c). It would therefore appear
that the action of o-vanillin on KCC is not via the regulatory phosphoryla-
tion cascade but more likely directly on the transporter itself.Control NEM
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Fig. 4.Effect of o-vanillin onKCC activity inN-ethylmaleimide (NEM)-treatedRBCs frompa-
tients with SCD. Oxygenated RBCs were pre-treated with NEM (1mM) for 30 min at 37 °C.
Controls were handled similarly but without addition of NEM. Cl−-dependent K+ inﬂux in
mmol (l cells h)−1 was then measured in the absence or presence of o-vanillin at the con-
centrations indicated. (a) & (b) KCC activity without or with 5 mM o-vanillin in RBCs from
HbSS or HbSC individuals, respectively; (c) concentration dependence of inhibition of KCC
activity in RBCs from HbSS individuals. Histograms represent means ± S.E.M., n = 3.The effect of o-vanillin on A23187-treated RBCs from SCD patients
In the previous experiments (Fig. 2), Gardos channel activity was
activated by deoxygenation, following Ca2+ entry through the
deoxygenation-induced Psickle activity. Under these conditions, the
magnitude of the CLT-sensitive K+ inﬂux was modest, at about
6 mmol (l cells h)−1, considerably below the peak values achievable
in RBCs following full activation of the channel. Using the ionophore
A23187 to load RBCs with Ca2+ [28] can achieve activities of several
hundred mmol (l cells h)−1. In fully oxygenated conditions, RBCs
were incubated with A23187 (4 μM) and an extracellular Ca2+ of
10 μM to give a free intracellular Ca2+ of about 20 μM, given the
usual Donnan ratio of about 1.4 [29]. Gardos channel activity of up
to 700 mmol K+ (l cells h)− was achieved which was still largely
abolished in the presence of 5 mM o-vanillin in both HbSS and
HbSC RBCs (Fig. 5a). The IC50 was about 1 mM whilst inhibition at
5 mMwas about 95% (Fig. 5b). Thus o-vanillin was also able to inhib-
it Gardos channel activity directly, and again this was irrespective of
any effect on HbS polymerisation or Psickle activity.
The effect of o-vanillin on Na+/K+ pump activity in RBCs from SCD patients
The Na+/K+ pump, although of much lower capacity and volume
regulatory signiﬁcance than KCC, Psickle and the Gardos channel, is nev-
ertheless also able to mediate net solute efﬂux from RBCs including
those from SCD patients. Thus, it may also participate in dehydration,HbSS HbSC
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Fig. 5. Effect of o-vanillin on Gardos channel activity in A23187-treated RBCs from patients
with SCD. Oxygenated RBCswere pre-treatedwith A23187 (10 μM) for 30min at 37 °C. CLT
(5 μM)-sensitive K+ inﬂux inmmol (l cells h)−1was thenmeasured in the absence or pres-
ence of o-vanillin at the concentrations indicated. (a) Gardos channel activity without or
with 5mM o-vanillin inRBCs fromHbSSorHbSC individuals, as indicated; (b) concentration
dependence of inhibition of Gardos channel activity in RBCs from HbSS individuals. Histo-
grams represent means ± S.E.M., n= 3.
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Fig. 7. Effect of o-vanillin on KCC andGardos channel activity in RBCs fromnormal HbAA in-
dividuals. Transporter activity wasmeasured as described in legends to Figs. 4 and 5 in con-
trol RBCs or RBCs treated with 5 mM o-vanillin during the period of ﬂuxmeasurement. CLT
(5 μM)-sensitive K+ inﬂuxes inmmol (l cells h)−1were taken as ameasure of Gardos chan-
nel activity andCl−-dependentK+ inﬂuxes as ameasure of KCCactivity. ForGardos channel,
RBCs were treated with A23187 and [Ca2+]o of 10 μM and ﬂuxes presented as ×10−2 of
their actual magnitude; for KCC, RBCs were untreated or exposed to 1 mM NEM prior to
ﬂux measurement. Histograms represent means ± S.E.M., n= 3.
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shown that phenylalanine benzyl esters, which share some structural
similaritieswith o-vanillin, inhibit theNa+/K+pumpof RBCs.We there-
fore investigated the effects of o-vanillin on this pump. Results are
shown in Fig. 6. For RBCs from both HbSS and HbSC patients, control
Na+/K+ pumping activity gave an ouabain-sensitive K+ inﬂux of
about 4 mmol (l cells h)−, around 50% higher than usually observed in
normal RBCs. In the presence of o-vanillin, inhibition of pump activity
in RBCs from both genotypes was about 80% (Fig. 6).
Effect of o-vanillin on RBCs from normal individuals
To ascertain further whether HbS was involved in its effects on K+
permeability, o-vanillin was also tested on KCC and Gardos channel ac-
tivity on RBCs from normal HbAA individuals (Fig. 7). As in RBCs from
SCDpatients, KCCwas substantially inhibited inHbAARBCswhether ac-
tivated by swelling or by NEM (Fig. 7). Similarly, in A23187-treated nor-
mal RBCs, there was almost complete inhibition of Gardos channel
activity (Fig. 7).
Effect of o-vanillin on cell volume and K+ efﬂux
In the ﬁnal set of experiments, the effect of o-vanillin was tested on
RBC volume and K+ efﬂux. Following 60min deoxygenation, RBCs from
HbSS patients fell from 1.88 ± 0.01 to 1.74 ± 0.05 ml/g dcs in the ab-
sence of o-vanillin, and to 1.52 ± 0.01 in its presence. Notwithstanding
its inhibitory effects on the deﬁned K+ pathways, o-vanillin was there-
fore found to cause a reduction in RBC volume. K+ efﬂuxwas also found
to increase from 0.091 ± 0.012 h−1 to 0.192 ± 0.12 h−1.
Discussion
The present ms presents the ﬁrst evidence that, as well as reducing
HbS polymerisation and sickling, the aromatic aldehyde o-vanillin also
directly inhibits the main cation pathways which contribute towards
dehydration of HbS-containing RBCs. In particular, o-vanillin directly
inhibited both the KCl cotransproter (KCC) and the Ca2+-activated K+
channel (the Gardos channel) of RBCs from both HbSS and HbSC SCD
patients and normal individuals, and also the Na+/K+ pump. Results
also indicate partial inhibition of the third main pathway involved in
sickle cell dehydration, the deoxygenation-induced cation conductance
sometimes termed Psickle, independent of an effect on RBC sickling.
These ﬁndings indicate that aromatic aldehydes may protect sickle
cells by two distinct and potentially synergistic mechanisms: by
interacting directly with HbS to inhibit polymerisation and also inde-
pendently of any effect on Hb by reducing cation loss, maintaining
RBC hydration and hence reducing the concentration of HbS. The latterHbSS HbSC
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Fig. 6. Effect of o-vanillin on Na+/K+ pump activity in RBCs from patientswith SCD. Ouabain
(100 μM)-sensitive K+ inﬂux in mmol (l cells h)−1 was measured in fully oxygenated RBCs
from HbSS or HbSC individuals, as indicated. Histograms represent means ± S.E.M., n= 3.effects should be taken into account when designing potential thera-
peutic members of these compounds.
Despite being the commonest severe inherited disorder affecting
millions of peopleworldwide, treatment for SCD remains problematical.
As complications of SCD follow from polymerisation of HbS and RBC
sickling, there has been considerable effort directed at discovering
novel anti-sickling reagents.Many of these have been designed to inter-
act directly with HbS, to stabilise the oxy conformation (increasing O2
afﬁnity) and to inhibit polymerisation [9–11].
Various carbonyl compounds were shown to reduce RBC sickling
over forty years ago, with aromatic aldehydes more effective than ali-
phatic aldehydes [9]. The reactive aldehyde group is thought to form
Schiff bases with Hb amino groups, particularly the terminal α1val,
and thereby increase O2 afﬁnity. Amongst the most potent of the
aromatic aldehydes tested was o-vanillin [9,30]. Its isomer p-vanillin
(vanillin) is also thought to react withαHis103 to promote the oxy con-
formation, with possible other interactions at key sites of polymer con-
tact (βHis116 and βHis117). In vivo, although vanillin itself is poorly
absorbed, a pro-drugMX-1520 was shown to protect sickle rats against
hypoxia [31].
A number of substituted benzaldehydes, notably 12C79 (also known
as BW12C or valerosol) and 589C80 (BWA589C or tucaresol), were also
designed to act in a similar manner but with greater binding ability to
Hb [32–34]. In experiments involving cyclical deoxygenation and re-
oxygenation of sickle cells in vitro bothwere effective inmaintaining in-
tracellular K+, high MCV and better deformability [35]. Combination of
these benzaldehydes to act via reducing HbS depolymerisation along
with direct inhibition of the Gardos channel with clotrimazole and
nitrendipine was synergistic in protecting sickle RBCs from shrinkage
and K+ loss during episodes of cyclical deoxygenation [36]. In clinical
trials, 12C79 (valerosol) was effective in increasing O2 afﬁnity of Hb
both in normal HbAA individuals [37] and SCD patients [38] but had a
rather short half life. Although 589C80 (tucaresol) with its longer half
26 A. Hannemann et al. / Blood Cells, Molecules and Diseases 53 (2014) 21–26life and ability to improve haematological parameters in sickle patients,
side-effects included fever and cervical lymphadenopathy [39].
More recently, attention has turned to other potential anti-sickling
reagents. Amongst these are the heterocyclic aldehydes (furanic com-
pounds). They too have a similar action binding toα1val and also prob-
ably disrupting a key salt bridge with the C-terminal carboxyl group of
arg141α [11]. One of them, 5HMF was found to be several times more
potent than vanillin in inhibiting sickling [40]. It also protected sickle
mice from hypoxia [11]. These ﬁndings are very encouraging and cur-
rently, 5HMF is the subject of clinical trials in SCD patients.
During the development of these HbS reactive compounds, any ef-
fects on RBC permeability have received rather less attention. There
are indications, however, that this might be signiﬁcant. Thus, L-
phenylalanine benzyl ester, whichwas found to reduce sickling, appears
to partition into the RBC membrane and non-speciﬁcally inhibits trans-
port systems including the Na+/K+ pump, the cation cotransporters
(probably the Na+–K+–2Cl− cotransporter, NKCC) and the anion ex-
changer (AE1) whilst also increasing passive cation leaks [12]. No infor-
mation is available on the aromatic aldehydes.
The current results provide the ﬁrst evidence that o-vanillin directly
inhibits the RBC KCC, Gardos channel and Psickle. As reported, o-vanillin
was found to increase O2 afﬁnity and inhibit sickling, but their effects
on these permeability pathways do not depend on this action. Thus, for
KCC andGardos channel, inhibition also occurredwhen RBCswere treat-
ed with either the sulphydryl reacting reagent NEM or the Ca2+ iono-
phore A23187, manipulations which bypass any anti-sickling action of
o-vanillin. The Na+/K+ pump was also inhibited by o-vanillin. Although
this raises the possibility that it acts non-speciﬁcally, as suggested for the
phenylalanine benzyl esters [12], perhaps by partitioning into the mem-
brane and destabilising the transporters, the much reduced effect of its
isoform, para-vanillin (or usually simply vanillin) argues against this.
5HMF, currently in clinical trials in SCD patients, was different in effect,
at least in the transport assays carried out in this work. Nevertheless,
present ﬁndings indicate that it is possible to design aromatic aldehydes
which combine a direct inhibitory effect on HbS polymerisation together
with favourable effects on reduction of RBC permeability to thereby in-
crease RBC hydration. These dual effects may potentiate their ability to
ameliorate the complications of SCD.
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